Israel - inglés - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor s.k., co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event.limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Israel - inglés - Ministry of Health

propharm ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor propharm is indicated for co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Israel - inglés - Ministry of Health

propharm ltd - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor propharm is indicated for co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; sodium lauryl sulfate; calcium hydrogen phosphate dihydrate; iron oxide yellow; titanium dioxide; pregelatinised maize starch; mannitol; purified talc; glyceryl caprylate/caprate; polyvinyl alcohol; maize starch - ticagrelor sandoz, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Israel - inglés - Ministry of Health

novartis israel ltd - ticagrelor - film coated tablets - ticagrelor 90 mg - ticagrelor - ticagrelor sandoz®, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event.limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Israel - inglés - Ministry of Health

novartis israel ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - ticagrelor sandoz®, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event.limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: purified water; croscarmellose sodium; calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - ticagrelor, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Malta - inglés - Medicines Authority

abdi farma gmbh donnersbergstraße 4 64646 heppenheim, , germany - film-coated tablet - ticagrelor 60 mg - antithrombotic agents

Malta - inglés - Medicines Authority

abdi farma gmbh donnersbergstraße 4 64646 heppenheim, , germany - film-coated tablet - ticagrelor 90 mg - antithrombotic agents

Estados Unidos - inglés - NLM (National Library of Medicine)

the medicines company - cangrelor (unii: 6aq1y404u7) (cangrelor - unii:6aq1y404u7) - cangrelor 50 mg - kengreal is indicated as an adjunct to percutaneous coronary intervention (pci) to reduce the risk of periprocedural myocardial infarction (mi), repeat coronary revascularization, and stent thrombosis (st) in patients who have not been treated with a p2y12 platelet inhibitor and are not being given a glycoprotein iib/iiia inhibitor [see clinical studies ( 14.1 )]. kengreal is contraindicated in patients with significant active bleeding [see warnings and precautions ( 5.1 ) and adverse reactions ( 6.1 )] . kengreal is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to kengreal or any component of the product [see adverse reactions ( 6.1 )] . pregnancy category c there are no adequate and well-controlled studies of kengreal in pregnant women. cangrelor did not produce malformations in either the rat or rabbit reproductive studies, and is not considered to be a teratogen. in embryo-fetal development studies in rats, cangrelor produced dose-related fetal growth retardation characteri